Citations

Clear

4847 citation(s) found for "Tu, Eric".

Individual Patient Data Analysis of Progression-Free Survival Versus Overall Survival As a First-Line End Point for Metastatic Colorectal Cancer in Modern Randomized Trials: Findings From the Analysis and Research in Cancers of the Digestive System Databas
Shi, Qian , Gramont, Aimery de , Grothey, Axel, Zalcberg, John , Chibaudel, Benoist , Seymour, Michel , Adams, Richard , Saltz, Leonard B. , Goldberg, Richard M. , Punt, Cornelis J.A. , Douillard, Jean‐Yves , Hoff, Paulo M. , Hecht, J. Randolph, Hurwitz, Herbert I. , Díaz‐Rubio, Eduardo , Porschen, Rainer, Fuchs, Charles S. , Souglakos, John , Falcone, Alfredo , Tournigand, Christophe , Kabbinavar, Fairooz F. , Heinemann, Volker , Bokemeyer, Carsten , de Gramont, Aimery, Schmoll, Hans‐Joachim , Seymour, Matthew T, Saltz, Leonard, Hecht, Joel Randolph, Hurwitz, Herbert, Díaz-Rubio, Eduardo, Tebbutt, Niall C. , van Cutsem, Eric, Buyse, Marc , Cutsem, Eric Van , Sargent, Daniel J. , Saltz, Leonard , Shi, Qian , Falcone, Alfredo , Seymour, Matthew T , Zalcberg, John , Adams, Richard , Chibaudel, Benoist

Mayo Clinic

Journal of Clinical Oncology | November 11, 2014 | Volume: 33 | Issue: 1 | Pages: 22-28

10.1200/jco.2014.56.5887 | PMID 25385741 Get It

PurposeProgression-free survival (PFS) has previously been established as a surrogate for overall survival (OS) for first-line metastatic colorectal cancer (mCRC). Because mCRC treatment has advanced in the last decade with extended OS, this surrogacy requires re-examination.MethodsIndividual patient data from 16,762 patients were available from 22 first-line mCRC studies conducted from 1997 to 2006; 12 of those studies tested antiangiogenic and/or anti–epidermal growth factor receptor agents. The relationship between PFS (first event of progression or death) and OS was evaluated by using R2statistics (the closer the value is to 1, the stronger the correlation) from weighted least squares regression of trial-specific hazard ratios estimated by using Cox and Copula models.ResultsForty-four percent of patients received a regimen that included biologic agents. Median first-line PFS was 8.3 months, and median OS was 18.2 months. The correlation between PFS and OS was modest (R2, 0.45 to 0.69). Analyses limited to trials that tested treatments with biologic agents, nonstrategy trials, or superiority trials did not improve surrogacy.ConclusionIn modern mCRC trials, in which survival after the first progression exceeds time to first progression, a positive but modest correlation was observed between OS and PFS at both the patient and trial levels. This finding demonstrates the substantial variability in OS introduced by the number of lines of therapy and types of effective subsequent treatments and the associated challenge to the use of OS as an end point to assess the benefit attributable to a single line of therapy. PFS remains an appropriate primary end point for first-line mCRC trials to detect the direct treatment effect of new agents.
Time Trends in Incidence, Clinical Features, and Cardiovascular Disease in Ankylosing Spondylitis Over Three Decades: A Population‐Based Study
Wright, Kerry , Crowson, Cynthia S. , Michet, Clement J. , Matteson, Eric L. , Wright, Kerry A

Mayo Clinic

Arthritis Care & Research | November 10, 2014 | Volume: 67 | Issue: 6 | Pages: 836-841

10.1002/acr.22512 | PMID 25384671 Get It

ObjectiveTo determine trends in the incidence and clinical presentation of ankylosing spondylitis (AS), the incidence of cardiovascular disease (CVD), and cardiovascular (CV) risk factors among patients with AS and compare the observed incidence of CVD with that predicted by the Framingham Risk Score (FRS).MethodsA population‐based inception cohort of residents of Olmsted County, Minnesota age ≥18 years who fulfilled Modified New York Criteria for AS in 1980–2009 was assembled. Clinical features at presentation were recorded. Age‐ and sex‐adjusted incidence rates and survival were estimated. Incident CVD and CV risk factors were identified. The 10‐year CVD risk was calculated using the FRS. Standardized incidence ratios (ratios of observed CVD in AS to that predicted by the FRS) were calculated.ResultsEighty‐six patients were diagnosed with AS over the study period with an age‐ and sex‐adjusted incidence of 3.1 per 100,000 (95% confidence interval [95% CI] 2.5–3.8). The mean age at diagnosis was 35 years (range 19–69 years). Inflammatory back pain, seen in 90% of patients, was the most common presenting manifestation. The 10‐year mean ± SD cumulative incidence of CVD was 15.8% ± 6.1%, three times higher than the predicted events based on the FRS (standardized incidence ratio 3.01, 95% CI 1.35–6.69; P = 0.007). Overall survival was similar to the general population.ConclusionAS occurs in approximately 3 persons per 100,000 per year. Clinical features, extraarticular manifestations, and interval from symptom onset to diagnosis have remained constant in this population over the study period. The CVD risk in these patients is higher than expected and underestimated by the FRS.
Genetic Markers Associated With Plasma Protein C Level in African Americans: The Atherosclerosis Risk in Communities (ARIC) Study
Munir, Muhammad S., Weng, Lu‐Chen , Tang, Weihong , Basu, Saonli , Pankow, James S. , Matijevic, Nena, Cushman, Mary , Boerwinkle, Eric , Folsom, Aaron R. , Munir, M Shahzeb, Pankow, James S , Tang, Weihong

Mayo Clinic

Genetic Epidemiology | November 5, 2014 | Volume: 38 | Issue: 8 | Pages: 709-713

10.1002/gepi.21868 | PMID 25376901 Get It

Case-only exome sequencing and complex disease susceptibility gene discovery: study design considerations
Wu, Lang , Schaid, Daniel J. , Sicotte, Hugues , Wieben, Eric D. , Petersen, Gloria M. , Li, Hu

Mayo Clinic

Journal of Medical Genetics | November 4, 2014 | Volume: 52 | Issue: 1 | Pages: 10-16

10.1136/jmedgenet-2014-102697 | PMID 25371537 Get It

Whole exome sequencing (WES) provides an unprecedented opportunity to identify the potential aetiological role of rare functional variants in human complex diseases. Large-scale collaborations have generated germline WES data on patients with a number of diseases, especially cancer, but less often on healthy controls under the same sequencing procedures. These data can be a valuable resource for identifying new disease susceptibility loci if study designs are appropriately applied. This review describes suggested strategies and technical considerations when focusing on case-only study designs that use WES data in complex disease scenarios. These include variant filtering based on frequency and functionality, gene prioritisation, interrogation of different data types and targeted sequencing validation. We propose that if case-only WES designs were applied in an appropriate manner, new susceptibility genes containing rare variants for human complex diseases can be detected.
Epidemiology of Systemic Lupus Erythematosus and Cutaneous Lupus Erythematosus in a Predominantly White Population in the United States
Jarukitsopa, Sudumpai, Hoganson, Deana D., Crowson, Cynthia S. , Sokumbi, Olayemi , Davis, Mark D.P. , Michet, Clement J. , Matteson, Eric L. , Kremers, Hilal Maradit , Chowdhary, Vaidehi , Davis, Mark D., Maradit Kremers, Hilal, Chowdhary, Vaidehi R, Maradit Kremers, Hilal , Sokumbi, Olayemi

Mayo Clinic

Arthritis Care & Research | November 4, 2014 | Volume: 67 | Issue: 6 | Pages: 817-828

10.1002/acr.22502 | PMID 25369985 Get It

Objective Epidemiologic studies comparing the incidence and prevalence of systemic lupus erythematosus (SLE) and isolated cutaneous lupus erythematosus (CLE) are few. Olmsted County, Minnesota provides a unique setting for such a study owing to resources of the Rochester Epidemiology Project. We sought to describe and compare the incidence and prevalence of SLE and CLE from 1993–2005. Methods SLE cases were identified from review of medical records and fulfilled the 1982 American College of Rheumatology classification criteria. CLE cases included patients with classic discoid lupus erythematosus, subacute CLE, lupus panniculitis, and bullous lupus erythematosus. Age‐ and sex‐adjusted incidence and prevalence were standardized to the 2000 US white population. Results The age‐ and sex‐adjusted incidence of SLE (2.9 per 100,000; 95% confidence interval [95% CI] 2.0–3.7) was similar to that of CLE (4.2 per 100,000; 95% CI 3.1–5.2, P = 0.10). However, the incidence of CLE was 3 times higher than SLE in men (2.4 versus 0.8 per 100,000; P = 0.009). The age‐ and sex‐adjusted prevalence of CLE on January 1, 2006 was higher than that of SLE (70.4 versus 30.5 per 100,000; P < 0.001). The prevalences of CLE and SLE in women were similar, but the prevalence of CLE was higher in men than in women (56.9 versus 1.6 per 100,000; P < 0.001). The incidence of CLE rose steadily with age and peaked at 60–69 years. Conclusion The incidences of CLE and SLE are similar, but CLE is more common than SLE in men and in older adults. These findings may reflect differences in genetic or environmental etiology of CLE.
Classification of failure of limb salvage after reconstructive surgery for bone tumours
Ruggieri, Pietro , Windhager, Reinhard , Funovics, Philipp T. , Gibbons, C. L. M. H. , Hornicek, Francis J. , Temple, H. Thomas , Letson, G. Douglas , Henderson, Eric R. , O’Connor, Mary I. , Guo, Wei , Ruggieri, Pietro

Mayo Clinic

The Bone & Joint Journal | November 4, 2014 | Volume: 96-B | Issue: 11 | Pages: 1436-1440

10.1302/0301-620x.96b11.34747 | PMID 25371453 Get It

Previous classification systems of failure of limb salvage focused primarily on endoprosthetic failures and lacked sufficient depth for the effective study of the causes of failure. In order to address these inadequacies, the International Society of Limb Salvage (ISOLS) formed a committee to recommend revisions of the previous systems. The purpose of this study was to report on their recommendations. The modifications were prepared using an earlier, evidence-based model with subclassification based on the existing medical literature. Subclassification for all five primary types of failure of limb salvage following endoprosthetic reconstruction were formulated and a complementary system was derived for the failure of biological reconstruction. An additional classification of failure in paediatric patients was also described. Limb salvage surgery presents a complex array of potential mechanisms of failure, and a complete and precise classification of types of failure is required. Earlier classification systems lacked specificity, and the evidence-based system outlined here is designed to correct these weaknesses and to provide a means of reporting failures of limb salvage in order to allow the interpretation of outcome following reconstructive surgery. Cite this article: Bone Joint J 2014;96-B:1436–40.
Getting Maintenance of Certification to Work
Cook, David A. , Holmboe, Eric S. , Sorensen, Kristi J., Wilkinson, John M. , Berger, Richard A. , Berger, Richard A.

Mayo Clinic

JAMA Internal Medicine | November 3, 2014 | Volume: 175 | Issue: 1 | Pages: 35

10.1001/jamainternmed.2014.5437 | PMID 25365596 Get It

Biological Strategies for Improved Osseointegration and Osteoinduction of Porous Metal Orthopedic Implants
Lewallen, Eric A. , Riester, Scott M. , Kremers, Hilal Maradit , Dudakovic, Amel , Cohen, Robert C., Lewallen, David G. , Wijnen, André J. van , Lewallen, Eric Alexander, Bonin, Carolina A. , Kakar, Sanjeev , Westendorf, Jennifer J. , van Wijnen, Andre J , Maradit Kremers, Hilal

Mayo Clinic

Tissue Engineering Part B: Reviews | October 27, 2014 | Volume: 21 | Issue: 2 | Pages: 218-230

10.1089/ten.teb.2014.0333 | PMID 25348836 Get It

The biological interface between an orthopedic implant and the surrounding host tissue may have a dramatic effect upon clinical outcome. Desired effects include bony ingrowth (osseointegration), stimulation of osteogenesis (osteoinduction), increased vascularization, and improved mechanical stability. Implant loosening, fibrous encapsulation, corrosion, infection, and inflammation, as well as physical mismatch may have deleterious clinical effects. This is particularly true of implants used in the reconstruction of load-bearing synovial joints such as the knee, hip, and the shoulder. The surfaces of orthopedic implants have evolved from solid-smooth to roughened-coarse and most recently, to porous in an effort to create a three-dimensional architecture for bone apposition and osseointegration. Total joint surgeries are increasingly performed in younger individuals with a longer life expectancy, and therefore, the postimplantation lifespan of devices must increase commensurately. This review discusses advancements in biomaterials science and cell-based therapies that may further improve orthopedic success rates. We focus on material and biological properties of orthopedic implants fabricated from porous metal and highlight some relevant developments in stem-cell research. We posit that the ideal primary and revision orthopedic load-bearing metal implants are highly porous and may be chemically modified to induce stem cell growth and osteogenic differentiation, while minimizing inflammation and infection. We conclude that integration of new biological, chemical, and mechanical methods is likely to yield more effective strategies to control and modify the implant–bone interface and thereby improve long-term clinical outcomes.
Trastuzumab Plus Adjuvant Chemotherapy for Human Epidermal Growth Factor Receptor 2–Positive Breast Cancer: Planned Joint Analysis of Overall Survival From NSABP B-31 and NCCTG N9831
Perez, Edith A. , Romond, Edward H., Jeong, Jong‐Hyeon , Martino, Silvana, Rastogi, Priya , Swain, Sandra M. , Colón‐Otero, Gerardo , Davidson, Nancy E. , Mamounas, E., Zujewski, Jo Anne , Sledge, George, Geyer, Charles E. , Gralow, Julie, Mamounas, Eleftherios, Wolmark, Norman , Suman, Vera J. , Sledge, George W. , Gralow, Julie R. , Winer, Eric P. , Zujewski, Jo Anne , Swain, Sandra M

Mayo Clinic

Journal of Clinical Oncology | October 21, 2014 | Volume: 32 | Issue: 33 | Pages: 3744-3752

10.1200/jco.2014.55.5730 | PMID 25332249 Get It

Purpose Positive interim analysis findings from four large adjuvant trials evaluating trastuzumab in patients with early-stage human epidermal growth factor receptor 2 (HER2) –positive breast cancer were first reported in 2005. One of these reports, the joint analysis of North Central Cancer Treatment Group NCCTG N9831 (Combination Chemotherapy With or Without Trastuzumab in Treating Women With HER2-Overexpressing Breast Cancer) and the National Surgical Adjuvant Breast and Bowel Project NSABP B-31 (Doxorubicin and Cyclophosphamide Plus Paclitaxel With or Without Trastuzumab in Treating Women With Node-Positive Breast Cancer That Overexpresses HER2), was updated in 2011. We now report the planned definitive overall survival (OS) results from this joint analysis along with updates on the disease-free survival (DFS) end point. Methods In all, 4,046 patients with HER2-positive operable breast cancer were enrolled to receive doxorubicin and cyclophosphamide followed by paclitaxel with or without trastuzumab in both trials. The required number of events for the definitive statistical analysis for OS (710 events) was reached in September 2012. Updated analyses of overall DFS and related subgroups were also performed. Results Median time on study was 8.4 years. Adding trastuzumab to chemotherapy led to a 37% relative improvement in OS (hazard ratio [HR], 0.63; 95% CI, 0.54 to 0.73; P < .001) and an increase in 10-year OS rate from 75.2% to 84%. These results were accompanied by an improvement in DFS of 40% (HR, 0.60; 95% CI, 0.53 to 0.68; P < .001) and increase in 10-year DFS rate from 62.2% to 73.7%. All patient subgroups benefited from addition of this targeted anti-HER2 agent. Conclusion The addition of trastuzumab to paclitaxel after doxorubicin and cyclophosphamide in early-stage HER2-positive breast cancer results in a substantial and durable improvement in survival as a result of a sustained marked reduction in cancer recurrence.
2014 Report on the Milestones for the US National Plan to Address Alzheimer's Disease
Fargo, Keith N. , Aisen, Paul , Albert, Marilyn , Corrada, María M. , DeKosky, Steven T. , Drachman, David A., Fillit, Howard , Gitlin, Laura N. , Haas, Magali , Kawas, Claudia H. , Khachaturian, Ara S. , Khachaturian, Zaven S., Klunk, William E. , Kukull, Walter A. , Lamb, Bruce T. , Logsdon, Rebecca G., Maruff, Paul , Mesulam, Marsel, Mobley, William C. , Mohs, Richard C. , Nixon, Ralph A. , Paul, Steven M., Petersen, Ronald, Plassman, Brenda L. , Potter, William Z. , Reiman, Eric M. , Reisberg, ‌Barry , Sano, Mary , Schindler, Rachel, Schneider, Lon S. , Snyder, Peter J. , Yaffe, Kristine , Bain, Lisa J. , Thies, William, Carrillo, María C. , Au, Rhoda , Herrup, Karl , Knopman, David S. , Morgan, David , Petersen, Ronald, Sperling, Reisa Anne , Maruff, Paul

Mayo Clinic

Alzheimer's & Dementia | October 20, 2014 | Volume: 10 | Issue: 5S | Pages: No page available

10.1016/j.jalz.2014.08.103 | PMID 25341459 Get It

AbstractWith increasing numbers of people with Alzheimer's and other dementias across the globe, many countries have developed national plans to deal with the resulting challenges. In the United States, the National Alzheimer's Project Act, signed into law in 2011, required the creation of such a plan with annual updates thereafter. Pursuant to this, the US Department of Health and Human Services (HHS) released the National Plan to Address Alzheimer's Disease in 2012, including an ambitious research goal of preventing and effectively treating Alzheimer's disease by 2025. To guide investments, activities, and the measurement of progress toward achieving this 2025 goal, in its first annual plan update (2013) HHS also incorporated into the plan a set of short, medium and long‐term milestones. HHS further committed to updating these milestones on an ongoing basis to account for progress and setbacks, and emerging opportunities and obstacles. To assist HHS as it updates these milestones, the Alzheimer's Association convened a National Plan Milestone Workgroup consisting of scientific experts representing all areas of Alzheimer's and dementia research. The workgroup evaluated each milestone and made recommendations to ensure that they collectively constitute an adequate work plan for reaching the goal of preventing and effectively treating Alzheimer's by 2025. This report presents these Workgroup recommendations.